Human immunodeficiency virus and menopause

Menopause

Volumn 20, Issue 9, 2013, Pages 983-990

  Kanapathipillai, Rupa ^a   Hickey, Martha ^b   Giles, Michelle ^a,b,c  

^a ALFRED HOSPITAL   (Australia)

^b ROYAL WOMEN'S HOSPITAL   (Australia)

^c MONASH MEDICAL CENTRE   (Australia)

Author keywords

antiretroviral therapy; Bone; Cardiovascular; Combination; Human immunodeficiency virus; Inflammation; Menopause

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; VITAMIN D; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AGING; BONE DENSITY; BONE DISEASE; BONE TURNOVER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; COMORBIDITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MENOPAUSE; OSTEOPOROSIS; REVIEW; RISK ASSESSMENT; SYMPTOM; CARDIOVASCULAR DISEASES; HEALTH STATUS; HIV INFECTIONS; HIV SEROPOSITIVITY; MENTAL STRESS; METABOLIC SYNDROME X; MIDDLE AGED; WOMEN'S HEALTH;

AGING; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; CAUSALITY; COMORBIDITY; FEMALE; HEALTH STATUS; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; MENOPAUSE; METABOLIC SYNDROME X; MIDDLE AGED; STRESS, PSYCHOLOGICAL; WOMEN'S HEALTH;

EID: 84883655974     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0b013e318282aa57     Document Type: Review

References (116)

1. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372: 293-299.
2. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008;300:51-59.
3. May MT, Ingle SM. Life expectancy of HIV-positive adults: a review. Sex Health 2011;8:526-533.
4. May M, Sterne JA, Sabin C, et al. Prognosis of HIV-1Yinfected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007;21:1185-1197.
5. Ray M, Logan R, Sterne JA, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010;24:123-137.
6. Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIVinfected persons: the Swiss HIV Cohort Study. Clin Infect Dis 2011;53:1130-1139.
7. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011;53:1120-1126.
8. Jacobsen BK, Heuch I, Kvale G. Age at natural menopause and allcause mortality: a 37-year follow-up of 19,731 Norwegian women. Am J Epidemiol 2003;157:923-929.
9. Ossewaarde ME, Bots ML, Verbeek AL, et al. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology 2005; 16:556-562.
10. Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006;13:265-279.
11. de Kleijn MJ, van der Schouw YT, Verbeek AL, Peeters PH, Banga JD, van der Graaf Y. Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women. Am J Epidemiol 2002;155: 339-345.
12. Hu FB, Grodstein F, Hennekens CH, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 1999;159:1061-1066.
13. Jacobsen BK, Nilssen S, Heuch I, Kvale G. Does age at natural menopause affect mortality from ischemic heart disease? J Clin Epidemiol 1997;50:475-479.
14. van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD. Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996;347:714-718.
15. Jansen SC, Temme EH, Schouten EG. Lifetime estrogen exposure versus age at menopause as mortality predictor. Maturitas 2002;43:105-112.
16. Jacobsen BK, Knutsen SF, Fraser GE. Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study. J Clin Epidemiol 1999;52:303-307.
17. Parazzini F, Bidoli E, Franceschi S, et al. Menopause, menstrual and reproductive history, and bone density in northern Italy. J Epidemiol Community Health 1996;50:519-523.
18. Kritz-Silverstein D, Barrett-Connor E. Early menopause, number of reproductive years, and bone mineral density in postmenopausal women. Am J Public Health 1993;83:983-988.
19. van Der Voort DJ, van Der Weijer PH, Barentsen R. Early menopause: increased fracture risk at older age. Osteoporos Int 2003;14:525-530.
20. Mondul AM, Rodriguez C, Jacobs EJ, Calle EE. Age at natural menopause and cause-specific mortality. Am J Epidemiol 2005;162:1089-1097.
21. Clark RA, Cohn SE, Jarek C, et al. Perimenopausal symptomatology among HIV-infected women at least 40 years of age. J Acquir Immune Defic Syndr 2000;23:99-100.
22. Fantry LE, Zhan M, Taylor GH, Sill AM, Flaws JA. Age of menopause and menopausal symptoms in HIV-infected women. AIDS Patient Care STDS 2005;19:703-711.
23. Ferreira CE, Pinto-Neto AM, Conde DM, Costa-Paiva L, Morais SS, Magalhaes J. Menopause symptoms in women infected with HIV: prevalence and associated factors. Gynecol Endocrinol 2007;23:198-205.
24. Schoenbaum EE, Hartel D, Lo Y, et al. HIV infection, drug use, and onset of natural menopause. Clin Infect Dis 2005;41:1517-1524.
25. Cejtin HE, Kim S, Taylor RN, et al. Menopause in women in the Women's Interagency HIV Study (WIHS). Poster presented at the XV International AIDS Conference, Abstract WePeD6504; 2004. Available at: http://www.iasociety.org/ Default.aspx?pageId=11&abstractId=2169564. Accessed October 2, 2012.
26. de Pommerol M, Hessamfar M, Lawson-Ayayi S, et al. Menopause and HIV infection: age at onset and associated factors, ANRS CO3 Aquitaine cohort. Int J STD AIDS 2011;22:67-72.
27. Gold EB, Bromberger J, Crawford S, et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol 2001;153:865-874.
28. Fan MD, Maslow BS, Santoro N, Schoenbaum E. HIV and the menopause. Menopause Int 2008;14:163-168.
29. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012; 97:1159-1168.
30. Cejtin HE, Kalinowski A, Bacchetti P, et al. Effects of human immunodeficiency virus on protracted amenorrhea and ovarian dysfunction. Obstet Gynecol 2006;108:1423-1431.
31. Harlow SD, Schuman P, Cohen M, et al. Effect of HIV infection on menstrual cycle length. J Acquir Immune Defic Syndr 2000;24:68-75.
32. Clark RA, Mulligan K, Stamenovic E, et al. Frequency of anovulation and early menopause among women enrolled in selected adult AIDS clinical trials group studies. J Infect Dis 2001;184:1325-1327.
33. Cofrancesco J Jr, Shah N, Ghanem KG, et al. The effects of illicit drug use and HIV infection on sex hormone levels in women. Gynecol Endocrinol 2006;22:244-251.
34. Proceedings from the NIH State-of-the-Science Conference on Management of Menopause-Related Symptoms, March 21-23, 2005, Bethesda, Maryland, USA. Am J Med 2005;118(Suppl 12B):1-171.
35. Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of Women's Health Across the Nation. Am J Public Health 2006;96:1226-1235.
36. Bromberger JT, Kravitz HM. Mood and menopause: findings from the Study of Women's Health Across the Nation (SWAN) over 10 years. Obstet Gynecol Clin North Am 2011;38:609-625.
37. Bromberger JT, Kravitz HM, Chang YF, Cyranowski JM, Brown C, Matthews KA. Major depression during and after the menopausal transition: Study of Women's Health Across the Nation (SWAN). Psychol Med 2011;41:1879-1888.
38. Hickey M, Bryant C, Judd F. Evaluation and management of depressive and anxiety symptoms in midlife. Climacteric 2012;15:3-9.
39. Miller SA, Santoro N, Lo Y, et al. Menopause symptoms in HIVinfected and drug-using women. Menopause 2005;12:348-356.
40. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statisticsV2011 update: a report from the American Heart Association. Circulation 2011;123:e18-e209.
41. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIVinfected individuals. J Acquir Immune Defic Syndr 2003;33:506-512.
42. Lang S, Mary-Krause M, Cotte L, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 2010;24:1228-1230.
43. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007;92:2506-2512.
44. Saves M, Chene G, Ducimetiere P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003;37:292-298.
45. Sabin CA, d'Arminio Monforte A, Friis-Moller N, et al. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clin Infect Dis 2008;46:1101-1110.
46. Dolan SE, Hadigan C, Killilea KM, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr 2005;39:44-54.
47. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349: 1993-2003.
48. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-1735.
49. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371:1417-1426.
50. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virusYinfected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010;170:1228-1238.
51. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003;17:2479-2486.
52. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010;201:318-330.
53. Bedimo RJ, Westfall AO, Dreschler H, et al. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis 2011;53:84-91.
54. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ countYguided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-2296.
55. Sarwar N, Butterworth AS, Freitag DF, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012;379:1205-1213.
56. Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-140.
57. Danesh J, Whincup P, Walker M, et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 2001; 103:2323-2327.
58. Tilton JC, Johnson AJ, Luskin MR, et al. Diminished production of monocyte proinflammatory cytokines during human immunodeficiency virus viremia is mediated by type I interferons. J Virol 2006;80: 11486-11497.
59. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010;201:1788-1795.
60. Kaplan RC, Landay AL, Hodis HN, et al. Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment. J Acquir Immune Defic Syndr 2012;60:359-368.
61. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
62. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011;203: 780-790.
63. Tien PC, Choi AI, Zolopa AR, et al. Inflammation and mortality in HIVinfected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 2010;55:316-322.
64. Meier A, Chang JJ, Chan ES, et al. Sex differences in the Toll-like receptorYmediated response of plasmacytoid dendritic cells to HIV-1. Nat Med 2009;15:955-959.
65. Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. Clin Immunol 2010;134:33-46.
66. Kaplan RC, Sinclair E, Landay AL, et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 2011;203:452-463.
67. Baker JV, Henry WK, Patel P, et al. Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort. Clin Infect Dis 2011;53:826-835.
68. Kaplan RC, Kingsley LA, Sharrett AR, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis 2007;45:1074-1081.
69. Law MG, Friis-Moller N, El-Sadr WM, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 2006;7:218-230.
70. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847.
71. Friis-Moller N, Thiebaut R, Reiss P, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010;17:491-501.
72. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006;20: 2165-2174.
73. National Osteoporosis Foundation. America's Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation, Washington, DC: National Osteoporosis Foundation, 2002.
74. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General, Rockville, MD: Department Health and Human Services, Department of the Surgeon General, 2004.
75. Budhia S, Mikyas Y, Tang M, Badamgarav E. Osteoporotic fractures: a systematic review of U.S. healthcare costs and resource utilization. Pharmacoeconomics 2012;30:147-170.
76. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Santoro N, Schoenbaum EE. HIV infection and bone mineral density in middleaged women. Clin Infect Dis 2006;42:1014-1020.
77. Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 2008;93:861-868.
78. Bolland MJ, Grey AB, Gamble GD, Reid IR. Clinical Review #: low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin EndocrinolMetab 2007;92: 4522-4528.
79. Yin MT, McMahon DJ, Ferris DC, et al. Low bone mass and high bone turnover in postmenopausal human immunodeficiency virusYinfected women. J Clin Endocrinol Metab 2010;95:620-629.
80. Dolan SE, Huang JS, Killilea KM, Sullivan MP, Aliabadi N, Grinspoon S. Reduced bone density in HIV-infected women. AIDS 2004; 18:475-483.
81. Cauley JA, Danielson ME, Boudreau RM, et al. Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J Bone Miner Res 2007;22: 1088-1095.
82. Yin MT, Zhang CA, McMahon DJ, et al. Higher rates of bone loss in postmenopausal HIV-infected women: a longitudinal study. J Clin Endocrinol Metab 2012;97:554-562.
83. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009;51:554-561.
84. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavirlamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011;203:1791-1801.
85. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292:191-201.
86. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofoviremtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010;51:963-972.
87. Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009;23:817-824.
88. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)Yinfected versus nonYHIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93:3499-3504.
89. Yin MT, Shi Q, Hoover DR, et al. Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study. AIDS 2010; 24:2679-2686.
90. Yin MT, Lu D, Cremers S, et al. Short-term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr 2010;53:202-208.
91. Yong MK, Elliott JH, Woolley IJ, Hoy JF. Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients. J Acquir Immune Defic Syndr 2011;57:205-210.
92. Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIVinfected persons: the Swiss HIV Cohort Study. Clin Infect Dis 2011; 53:1130-1139.
93. Young B, Dao CN, Buchacz K, Baker R, Brooks JT. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis 2011;52:1061-1068.
94. Dao CN, Patel P, Overton ET, et al. Low vitamin D among HIVinfected adults: prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011;52: 396-405.
95. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:385-397.
96. Gazzola L, Comi L, Savoldi A, et al. Use of the FRAX equation as firstline screening of bone metabolism alteration in the HIV-infected population. J Infect Dis 2010;202:330-331; author reply, 331-332.
97. Hickey M, Elliott J, Davison SL. Hormone replacement therapy. BMJ 2012;344:e763.
98. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-2063.
99. Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol 2009;200:238.e1-238.e10.
100. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289:2827-2834.
101. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578-1583.
102. Barton DL, LaVasseur BI, Sloan JA, et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 2010;28:3278-3283.
103. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebocontrolled trial. Lancet 2005;366:818-824.
104. Reddy SY, Warner H, Guttuso T Jr, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006;108:41-48.
105. Ayers B, Smith M, Hellier J, Mann E, Hunter MS. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial. Menopause 2012;19:749-759.
106. Sturdee DW, Pines A, Archer DF, et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011;14:302-320.
107. Adeyemi OM, Agniel D, French AL, et al. Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States. J Acquir Immune Defic Syndr 2011;57:197-204.
108. Avenell A, Gillespie WJ, Gillespie LD, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2009:CD000227.
109. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005;293:2257-2264.
110. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al. Fall prevention with supplemental and active forms of vitamin D: a metaanalysis of randomised controlled trials. BMJ 2009;339:b3692.
111. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis, Washington, DC: National Osteoporosis Foundation, 2010:2010. Accessed December 14, 2011.
112. Lin D, Rieder MJ. Interventions for the treatment of decreased bone mineral density associated with HIV infection. Cochrane Database Syst Rev 2007:CD005645.
113. McComsey GA, Kendall MA, Tebas P, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 2007;21:2473-2482.
114. Mondy K, Powderly WG, Claxton SA, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 2005;38:426-431.
115. Negredo E, Martinez-Lopez E, Paredes R, et al. Reversal of HIV-1Yassociated osteoporosis with once-weekly alendronate. AIDS 2005;19: 343-345.
116. Dolan Looby SE, Collins M, Lee H, Grinspoon S. Effects of long-term testosterone administration in HIV-infected women: a randomized, placebo-controlled trial. AIDS 2009;23:951-959.